You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Baxter
Mallinckrodt
McKesson
Colorcon

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for AP1903

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for AP1903?

AP1903 is an investigational drug.

There have been 24 clinical trials for AP1903. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2018.

The most common disease conditions in clinical trials are Preleukemia, Myelodysplastic Syndromes, and Leukemia, Lymphoid. The leading clinical trial sponsors are Bellicum Pharmaceuticals, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are two US patents protecting this investigational drug and twenty-one international patents.

Recent Clinical Trials for AP1903
TitleSponsorPhase
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST TrialNational Cancer Institute (NCI)Phase 1
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid TumorsCenter for Cell and Gene Therapy, Baylor College of MedicinePhase 1
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid TumorsBaylor College of MedicinePhase 1

See all AP1903 clinical trials

Clinical Trial Summary for AP1903

Top disease conditions for AP1903
Top clinical trial sponsors for AP1903

See all AP1903 clinical trials

US Patents for AP1903

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AP1903   Start Trial Synthetic multimerizing agents ARIAD Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
AP1903   Start Trial Synthetic multimerizing agents ARIAD Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Baxter
Mallinckrodt
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.